7 – 9 February 2018 Madrid
| 4-P | PREVALENCE OF VITAMIN D DEFICIENCY IN PERSONS WITH SEVERE HAEMOPHILIA IN IRELAND | Deirdre Gorman | |
| 5-P | CHRONIC PAIN IN HAEMOPHILIA:EVIDENCE BASED PSYCHOLOGICAL APPROACHES TO BETTER MANAGEMENT | Cleary Janet | |
| 6-P | PERSISTENT EFFECTIVENESS OF PROPHYLAXIS WITH RECOMBINANT FACTOR VIII CONCENTRATE IN PATIENTS WITH HEMOPHILIA A IN A REAL WORLD SETTING OVER 4 YEARS (INTERNATIONAL AHEAD STUDY) | Dana Scott | |
| 14-P | OUTPATIENT PHYSIOTERAPIC MANAGEMENT AT BIANCHI BONOMI HEMOFILIA CENTER: 20-YEAR EXPERIENCE | Boccalandro Elena | |
| 21-P | SAFETY AND EFFECTIVENESS OF FASCIAL THERAPY IN ADULT PATIENTS WITH HEMOPHILIC ARTHROPATHY OF ANKLE. A COHORT STUDY. | Rubén Cuesta-Barriuso | |
| 22-P | SAFETY AND EFFICACY OF MANUAL AND EDUCATIONAL THERAPY IN THE TREATMENT OF HEMOPHILIC ARTHROPATHY OF THE ELBOW. A RANDOMIZED CLINICAL TRIAL. | Rubén Cuesta-Barriuso | |
| 30-P | HEALTH RELATED QUALITY OF LIFE, DEVELOPMENTAL MILESTONES AND SELF-ESTEEM IN YOUNG ADULTS WITH CONGENITAL BLEEDING DISORDERS | Lotte Haverman | |
| 41-P | BLEEDING RISK IN HEMOPHILIA PATIENT UNDERGOING ANTITHROMBOTIC THERAPY, RESULTS OF THE EHREA MULTICENTRIC STUDY | ALEXANDRE DESJONQUERES | |
| 43-P | COMPARISON OF THREE ASSAYS FOR MEASURING FACTOR IX | Amy DERICQUEBOURG | |
| 49-P | CLINICAL REVIEW OF PIVOTAL TRIALS ON OCTOCOG-ALFA (KOVALTRY) AND OTHER RECOMBINANT FVIII IN PATIENTS WITH HAEMOPHILIA A | Lucia Sara DAngiolella | |
| 51-P | BENEFITS OF SWITCH TO FVIII-FC: EXPERIENCE OF PROPHYLAXIS IN EIGHT PATIENTS | annarita tagliaferri | |
| 53-P | THE FIX:C ASSESSMENT OF EXTENDED HALF-LIFE RECOMBINANT FACTOR IX PRODUCTS IN CLINICAL PRACTICE | Annette Bowyer | |
| 55-P | Comparison of Standard Half-Life to Extended Half-Life FIX Products: Real-World Analysis of Recent Factor IUs Dispensed and Expenditures in On-Demand Hemophilia B Patients | Ashley Daset | |
| 60-P | IMPACT OF PRE-EXISTING IMMUNITY TO AAV5 ON PHARMACODYNAMICS OF BMN 270, AN AAV5-BASED GENE THERAPY FOR THE TREATMENT OF HEMOPHILIA A | Simin Batroff | |
| 61-P | INTERIM ANALYSIS OF IMMUNOGENICITY TO THE VECTOR CAPSID AND TRANSGENE-EXPRESSED HUMAN FVIII IN A PHASE-1/2 CLINICAL STUDY OF BMN-270, AN AAV5 MEDIATED GENE THERAPY FOR HEMOPHILIA A | Simin Batroff | |
| 68-P | PATIENTS WITH BLEEDING OF UNKNOWN CAUSE AND JOINT HYPERMOBILITY: CLINICAL ASSESSMENT AND GENETIC SCREENING | marta Martorell | |
| 71-P | PREVALENCE OF OVERWEIGHT IN YOUNG PATIENTS WITH SEVERE HAEMOPHILIA AND ITS ECONOMIC BURDEN IN GERMANY | Christoph Bidlingmaier | |
| 75-P | THE WFH WORLD BLEEDING DISORDERS REGISTRY | Mark Brooker | |
| 83-P | PATIENT PERSPECTIVES ON CURRENT AND FUTURE HAEMOPHILIA TREATMENT | Erna van Balen | |
| 85-P | DRUG CONSUMPTION AND COST ESTIMATES FOR DIFFERENT RECOMBINANT FACTOR VIII PRODUCTS APPROVED FOR REPLACEMENT TREATMENT IN PATIENTS WITH HEMOPHILIA A IN ITALY | Alessandro ROGGERI | |
| 97-P | PERIPROSTHETIC BONE MINERAL DENSITY AFTER ANKLE PROTHESIS. PRELIMINARY OBSERVATIONS FROM TWO CLINICAL CASES. | Giulia Rebagliati | |
| 114-P | ASSOCIATED IMPACT OF ACTIVITY IMPAIRMENT ON CLINICAL AND PATIENT-CENTRIC OUTCOMES IN SEVERE HAEMOPHILIA | Aji NAIR | |
| 115-P | ASSOCIATED IMPACT OF WORK IMPAIRMENT ON CLINICAL AND PATIENT-CENTRIC OUTCOMES IN SEVERE HAEMOPHILIA | Aji NAIR | |
| 117-P | RECOMBINANT VON WILLEBRAND FACTOR (RVWF) ADMINISTRATION: DOSING CONSIDERATIONS AND RAPID STABILIZATION OF ENDOGENOUS PLASMA FVIII LEVELS IN PATIENTS WITH SEVERE VON WILLEBRAND DISEASE | Dana Scott | |
| 118-P | DOES ADAMTS13 INFLUENCE THE BLEEDING PHENOTYPE IN PATIENTS WITH VON WILLEBRAND DISEASE? | Johan Boender | |
| 121-P | SIMULTANEOUS THROMBIN AND PLASMIN GENERATION IN PATIENTS WITH PLASMINOGEN OR PLASMINOGEN ACTIVATOR INHIBITOR TYPE 1 DEFICIENCY | Joline Saes | |
| 122-P | WHOLE EXOME SEQUENCING IN PATIENTS WITH A BLEEDING TENDENCY | Joline Saes | |
| 125-P | ONLINE COURSE OF PHARMACOKINETIC MONITORING IN HEMOPHILIA WITH APPLICATION IN THE CLINICAL PRACTICE | Juan Eduardo Megías Vericat | |
| 126-P | INDIVIDUALIZATION OF PROPHYLAXIS WITH RECOMBINANT FACTOR VIII IN SEVERE OR MODERATE HEMOPHILIA A | Juan Eduardo Megías Vericat | |
| 128-P | PHYSICAL ACTIVITY AND HEALTH OUTCOMES IN SEVERE HEMOPHILIA A PATIENTS ON PROPHYLAXIS WITH CONVENTIONAL RFVIII VS. RFVIIIFC | Nanxin Li | |
| 129-P | CASE REPORT: A SUCCESSFUL PREGNANCY IN HAEMOPHILLIA A | Jun Yong | |
| 145-P | INSIGHT INTO THE REAL-LIFE OF PERSONS WITH HAEMOPHILIA (PWH).IMPACT OF RECENTLY INTRODUCED PROPHYLACTIC REPLACEMENT | Margit Serban | |
| 150-P | DOES BLOOD GROUP 0 INFLUENCE INHIBITOR DEVELOPMENT? DATA FROM THE PEDNET REGISTRY | Marloes de Kovel | |
| 152-P | F9 GENOTYPE AND PK HEMOPHILIA B ITALIAN STUDY (GEPKHIS | Massimo Morfini | |
| 154-P | HEMOPHILIACS MANAGEMENT IN AN EMERGENCY DEPARTMENT:A 7-YEARS SURVEY TO IDENTIFY AREAS FOR SAFETY AND QUALITY IMPROVEMENT. | Michael HOANG | |
| 156-P | JOINT OUTCOME IN FOUR YEARS FOLLOW-UP IN CHILDREN WITH HEMOPHILIA TREATED WITH EARLY PROPHYLAXIS | Minna Koskenvuo | |
| 158-P | PLATELETS DISORDER IN A CASE OF CHRONIC LYMPHOCYTIC LEUKEMIA (LLC) | Corrado Lodigiani | |
| 163-P | AUDIT OF BLEEDING COMPLICATIONS FOLLOWING INVASIVE PROCEDURES AND MINOR SURGERIES IN PATIENTS WITH BLEEDING DISORDERS: CONSIDERING A RATIONALE FOR SAFE SAME DAY DISCHARGE | Naoimh Herlihy | |
| 165-P | EFFICACY ON PAIN OF A SINGLE INJECTION OF HYALURONIC ACID IN HAEMOPHILIC ARTHROPATHY OF THE ANKLE: A PROSPECTIVE STUDY | Castet Sabine | |
| 177-P | ANNUAL BLEEDING RATE AND BLEEDING-RELATED FACTOR-REPLACEMENTTHERAPYCOSTS IN HEMOPHILIA A AND B IN REAL-LIFE CLINICAL PRACTICE: A 4-YEAR FOLLOW-UP STUDY IN FINLAND | Riitta Lassila | |
| 179-P | REAL-WORLD BLEEDING FREQUENCY IN INHIBITOR PATIENTS ON PROPHYLAXIS WITH APCC: DATA READ-OUT OF THE FEIBA GLOBAL OUTCOMES STUDY (FEIBA GO) | Dana Scott | |
| 180-P | TOLERABILITY/SAFETY OF FEIBA RECONSTITUTED IN REGULAR OR 50 REDUCED VOLUME AND FASTER INFUSION RATES: RATIONALE AND STUDY DESIGN IN PATIENTS WITH HEMOPHILIA A OR B WITH INHIBITORS | Dana Scott | |
| 181-P | REAL WORLD USE OF B-DOMAINDELETED, PORCINE-SEQUENCE FACTOR VIII (RPFVIII) IN PATIENTS WITH ACQUIRED HAEMOPHILIA A (AHA): POST-MARKETING SAFETY (PMS) STUDIES IN EUROPEAN UNION (EU) AND IN THE UNITED STATES (US) | Dana Scott | |
| 184-P | COMBINED PROTHROMBIN AND FACTOR XI DEFICIENCY IN A LEBANESE FAMILY | Roula Farah | |
| 186-P | MEASUREMENT OF JOINT STATUS IN PATIENTS WITH HAEMOPHILIA: A SYSTEMATIC REVIEW OF THE MEASUREMENT PROPERTIES OF HAEMOPHILIA-SPECIFIC JOINT EXAMINATION SCORES | Samantha Gouw | |
| 191-P | RECOMBINANT FVIII PRODUCT TYPE AND THE RISK OF INHIBITOR DEVELOPMENT IN PREVIOUSLY TREATED PATIENTS WITH HEMOPHILIA A: A SYSTEMATIC REVIEW AND META-ANALYSIS | Shermarke Hassan | |
| 196-P | THERAPEUTIC LEVELS OF HUMAN FVIII IN MICE AND PRIMATES AND NORMALIZATION OF BLEEDING IN HEMOPHILIC MICE FOLLOWING GENE THERAPY WITH BMN 270 | Sylvia Fong | |
| 197-P | MANAGMENT OF DELIVERIES IN CARRIERS FOR HEMOPHILA A AND LOW FVIII LEVELS WITH RECOMBINANT FVIIIFC FUSION PROTEIN | Susan Halimeh | |
| 202-P | SURGICAL INTERVENTIONS IN PATIENTS WITH HEMOPHILIA: OUTCOME OF TREATMENT AT A SINGLE CENTER IN LOW-RESOURCE SETTINGS | Tuan NGUYEN | |
7 – 9 February 2018 Madrid

Digital Object Identifier. Official code used to identify documents published on internet; similar to ISBN for books. You may use this code to reference your poster in future scientific publications or CVs. It can be found from anywhere in the world. To find the poster page, log onto www.medra.org and enter the DOI, or enter in your internet browser https://dx.doi.org/ followed by the DOI string asigned to your congress. |
||||
|
|